South Korea Study: KPV Reduced Fat Cell Conversion and Protected Mice on High-Fat Diet

[AlexSilver]

A new KPV study worth a look!

A team in South Korea worked with cells capable of becoming fat cells on demand. After setting that transformation in motion, they introduced KPV.

With KPV present, the number of cells completing the switch was much lower.

Intracellular fat fell by about 50%. Across all doses tested, the cells remained fully healthy.

Next, mice were placed on a high-fat diet for 4 weeks while receiving oral KPV every other day.

The KPV group showed reduced weight gain, smaller fat pads, lighter livers, better cholesterol and triglyceride readings, and liver stress markers that remained close to normal rather than rising 3-fold.


https://www.sciencedirect.com/science/article/abs/pii/S0040816626005318?via%3Dihub

 

[ladyj779]

KPV really seems capable of anything

 

[spanky2026]

And guess who started a KPV protocol today?!

 

[ladyj779]

spanky2026 said:

And guess who started a KPV protocol today?!

Don't run away! KPV is forever

 

[Mayostardayonnaise]

Looks like that's about to get torn apart once more

 

[spanky2026]

ladyj779 said:


No run! KPV FOR ALWAYS

Click to expand...

Actually, what I had in mind was the very first time anyone uses it. Still, fair enough — these days KPV seems to behave the way Tirz does, with fresh impressive benefits turning up practically every time you look.

 

[px1984]

KPV belongs in every single day's routine, no exceptions.

 

[PurpleSage]

KPV for the win!

 

[Calm Logic]

AlexSilver said:

A new KPV study worth a look!

A team in South Korea worked with cells capable of becoming fat cells on demand. After setting that transformation in motion, they introduced KPV.

With KPV present, the number of cells completing the switch was much lower.

Intracellular fat fell by about 50%. Across all doses tested, the cells remained fully healthy.

Next, mice were placed on a high-fat diet for 4 weeks while receiving oral KPV every other day.

The KPV group showed reduced weight gain, smaller fat pads, lighter livers, better cholesterol and triglyceride readings, and liver stress markers that remained close to normal rather than rising 3-fold.


https://www.sciencedirect.com/science/article/abs/pii/S0040816626005318?via%3Dihub

AOD works well in mice as well. I don't mean to sound doubtful:

Gemini said:


The human evidence for KPV is derived strictly from human cell line studies (in vitro), ex vivo human tissue explants, and related parent-molecule trials.

The single biggest concern regarding the systemic efficacy of subcutaneous (SubQ) KPV in humans is extreme enzymatic instability and rapid plasma clearance.

When a drug or peptide enters the bloodstream, tissues, or digestive tract, naturally occurring enzymes target and chop chemical bonds to recycle amino acids. If a molecule has high enzymatic instability, these enzymes break it apart before it can reach its target receptors or carry out its intended biological function.

Click to expand...

Put differently, getting KPV to deliver effectively might call for some engineering:




Has anyone come across (CKPV)₂ ?



While researching KPV, I noticed a next-gen version with greater efficacy. Does anyone have firsthand experience with it? Cheers

GLP1Chat.com

lessthanhalf said:

Nearly every active study on KPV is focused on tweaking the molecule to change how it behaves — think assorted nanoparticles, pairing it with another active compound, or the doubled KPV form that came up. Clearly, there are hurdles in delivering enough of it to the correct gut locations before digestive enzymes degrade it. On top of that, patenting a modified variant is presumably simpler. There is no proof that any of these tailored forms can be obtained; while most trials demonstrate it functions, I have not seen anything indicating that any iteration is nearing human testing, so a grey-market option seems highly improbable.

 

[FartfulCodger]

Perhaps I'll get lucky and the Eloralintide I'm waiting for will turn out to be KPV. Crazier things have occurred.

 

[peterpayne]

FartfulCodger said:

Perhaps I'll get lucky and the Eloralintide I'm waiting for will turn out to be KPV. Crazier things have occurred.

wow, I've had to stop buying anything that isn't strictly necessary for now and the coming months, so with any luck by the time things get better for me Elora will cost less and we can count on it being that.

 

[peterpayne]

Calm Logic said:

AlexSilver said:

A new KPV study worth a look!

A team in South Korea worked with cells capable of becoming fat cells on demand. After setting that transformation in motion, they introduced KPV.

With KPV present, the number of cells completing the switch was much lower.

Intracellular fat fell by about 50%. Across all doses tested, the cells remained fully healthy.

Next, mice were placed on a high-fat diet for 4 weeks while receiving oral KPV every other day.

The KPV group showed reduced weight gain, smaller fat pads, lighter livers, better cholesterol and triglyceride readings, and liver stress markers that remained close to normal rather than rising 3-fold.


https://www.sciencedirect.com/science/article/abs/pii/S0040816626005318?via%3Dihub

AOD works well in mice as well. I don't mean to sound doubtful:

Gemini said:


The human evidence for KPV is derived strictly from human cell line studies (in vitro), ex vivo human tissue explants, and related parent-molecule trials.

The single biggest concern regarding the systemic efficacy of subcutaneous (SubQ) KPV in humans is extreme enzymatic instability and rapid plasma clearance.

When a drug or peptide enters the bloodstream, tissues, or digestive tract, naturally occurring enzymes target and chop chemical bonds to recycle amino acids. If a molecule has high enzymatic instability, these enzymes break it apart before it can reach its target receptors or carry out its intended biological function.

Click to expand...

Put differently, getting KPV to deliver effectively might call for some engineering:




Has anyone come across (CKPV)₂ ?



While researching KPV, I noticed a next-gen version with greater efficacy. Does anyone have firsthand experience with it? Cheers

View attachment 12549


GLP1Chat.com

lessthanhalf said:

Nearly every active study on KPV is focused on tweaking the molecule to change how it behaves — think assorted nanoparticles, pairing it with another active compound, or the doubled KPV form that came up. Clearly, there are hurdles in delivering enough of it to the correct gut locations before digestive enzymes degrade it. On top of that, patenting a modified variant is presumably simpler. There is no proof that any of these tailored forms can be obtained; while most trials demonstrate it functions, I have not seen anything indicating that any iteration is nearing human testing, so a grey-market option seems highly improbable.

holding onto some skepticism matters in a world where you might end up buying vials that contain nothing at all...

 

[Calm Logic]

peterpayne said:

Calm Logic said:

AlexSilver said:

A new KPV study worth a look!

A team in South Korea worked with cells capable of becoming fat cells on demand. After setting that transformation in motion, they introduced KPV.

With KPV present, the number of cells completing the switch was much lower.

Intracellular fat fell by about 50%. Across all doses tested, the cells remained fully healthy.

Next, mice were placed on a high-fat diet for 4 weeks while receiving oral KPV every other day.

The KPV group showed reduced weight gain, smaller fat pads, lighter livers, better cholesterol and triglyceride readings, and liver stress markers that remained close to normal rather than rising 3-fold.


https://www.sciencedirect.com/science/article/abs/pii/S0040816626005318?via%3Dihub

AOD works well in mice as well. I don't mean to sound doubtful:

Gemini said:


The human evidence for KPV is derived strictly from human cell line studies (in vitro), ex vivo human tissue explants, and related parent-molecule trials.

The single biggest concern regarding the systemic efficacy of subcutaneous (SubQ) KPV in humans is extreme enzymatic instability and rapid plasma clearance.

When a drug or peptide enters the bloodstream, tissues, or digestive tract, naturally occurring enzymes target and chop chemical bonds to recycle amino acids. If a molecule has high enzymatic instability, these enzymes break it apart before it can reach its target receptors or carry out its intended biological function.

Click to expand...

Put differently, getting KPV to deliver effectively might call for some engineering:




Has anyone come across (CKPV)₂ ?



While researching KPV, I noticed a next-gen version with greater efficacy. Does anyone have firsthand experience with it? Cheers

View attachment 12549


GLP1Chat.com

lessthanhalf said:

Nearly every active study on KPV is focused on tweaking the molecule to change how it behaves — think assorted nanoparticles, pairing it with another active compound, or the doubled KPV form that came up. Clearly, there are hurdles in delivering enough of it to the correct gut locations before digestive enzymes degrade it. On top of that, patenting a modified variant is presumably simpler. There is no proof that any of these tailored forms can be obtained; while most trials demonstrate it functions, I have not seen anything indicating that any iteration is nearing human testing, so a grey-market option seems highly improbable.

holding onto some skepticism matters in a world where you might end up buying vials that contain nothing at all...

As an extra precaution, I use it too, hoping it keeps ISRs from happening with peptides that sting. My KPV gets reconstituted with saline BAC, then goes into a syringe alongside something such as GHK-Cu or NAD+. Even so, my doubts about this approach have grown.

 

[lessthanhalf]

AlexSilver said:

A new KPV study worth a look!

A team in South Korea worked with cells capable of becoming fat cells on demand. After setting that transformation in motion, they introduced KPV.

With KPV present, the number of cells completing the switch was much lower.

Intracellular fat fell by about 50%. Across all doses tested, the cells remained fully healthy.

Next, mice were placed on a high-fat diet for 4 weeks while receiving oral KPV every other day.

The KPV group showed reduced weight gain, smaller fat pads, lighter livers, better cholesterol and triglyceride readings, and liver stress markers that remained close to normal rather than rising 3-fold.


https://www.sciencedirect.com/science/article/abs/pii/S0040816626005318?via%3Dihub

Sadly, just the abstract is available. Does anyone happen to have the full study? I'm curious about the oral dose administered to the mice, since I suspect there are major problems with achieving sufficient dosing to be effective. From what I recall, at least a few of the mouse studies that used oral KPV gave rather large doses, which simply aren't feasible for people—certainly not at current pricing.

 

[AlexSilver]

lessthanhalf said:

AlexSilver said:

A new KPV study worth a look!

A team in South Korea worked with cells capable of becoming fat cells on demand. After setting that transformation in motion, they introduced KPV.

With KPV present, the number of cells completing the switch was much lower.

Intracellular fat fell by about 50%. Across all doses tested, the cells remained fully healthy.

Next, mice were placed on a high-fat diet for 4 weeks while receiving oral KPV every other day.

The KPV group showed reduced weight gain, smaller fat pads, lighter livers, better cholesterol and triglyceride readings, and liver stress markers that remained close to normal rather than rising 3-fold.


https://www.sciencedirect.com/science/article/abs/pii/S0040816626005318?via%3Dihub

Sadly, just the abstract is available. Does anyone happen to have the full study? I'm curious about the oral dose administered to the mice, since I suspect there are major problems with achieving sufficient dosing to be effective. From what I recall, at least a few of the mouse studies that used oral KPV gave rather large doses, which simply aren't feasible for people—certainly not at current pricing.

I looked into this, and from what I can tell the paper is still "ahead-of-print" — it hasn't shown up on PubMed/PMC yet. It's also closed-access, and Unpaywall reports no free full text.

I also tried using paid Claude to track it down. Its response was that "the mouse-model methodology details, dosing, and full data will require institutional access or a direct request to the authors to get beyond this abstract."

 

[lastresort]

My folks out here practicing sorcery yet again...first a museum dedicated to poop, now this....